Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Bendamustine Versus Fludarabine and Cyclophosphamide for Lymphodepletion Prior to CAR-T Therapy

Blood (2023) 142 (Supplement 1): 3504.

https://doi.org/10.1182/blood-2023-190388

Published: 2023

Journal Articles

Standardization of Outpatient Care after CAR-T Therapy across a Large Cell Therapy Network- through Technology and Decentralized Virtual Nurses: Preliminary Results

Blood (2023) 142 (Supplement 1): 254.

https://doi.org/10.1182/blood-2023-187253

Published: 2023

Journal Articles

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Minoo Battiwalla, MD, Carlos Bachier, MD, Vikas Bhushan, MD, Michael J. Eckrich, MD MPH, Alireza Eghtedar, MD, Haydar Frangoul, MD, Suman Kambhampati, MD, Shahbaz Malik, MD, Peter A. McSweeney, MD, Jeremy Pantin, MBBS, Aravind Ramakrishnan, MD, Hana Safah, MD, Paul J Shaughnessy, MD, Betsy Blunk, BSN, RN, BMTCN, Tonya Cox, BSN, RN, Rocky Billups, MS, Charles F. Lemaistre, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-139121

Published: 2020

Journal Articles

Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled Study

Charles F. Lemaistre, MD, Ju-Hsien Chao, DO, Tonya Cox, BSN, RN, Jose Carlos Cruz, MD, William B. Donnellan, MD, Alireza Eghtedar, MD, Jared Holder, MA, Suman Kambhampati, MD, Shahbaz Malik, Michael B. Maris, MD, Marcello Rotta, MD, Frank Thomas Slovick, MD, Minoo Battiwalla, MD

Blood (2019) 134 (Supplement_1): 4780.

https://doi.org/10.1182/blood-2019-130640

Published: 2019

Journal Articles

Do Hematopoietic Cell Transplant Patients Treated on a Clinical Trial Do Better? Comparison of Characteristics and Outcomes of Patients Enrolled Versus Not Enrolled on Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial

Blood (2014) 124 (21): 209.

https://doi.org/10.1182/blood.V124.21.209.209

Published: 2014

Journal Articles

The VIP (Very Immunocompromised Patient) Protocol: Improved Access To Care and Time To Antibiotics

Paul J. Shaughnessy, MD, Ann Kelley, RN, Roberta Tremper, RN, Jonathan Tinker, Carlos Bachier, MD, Joseph Holahan, MD, Roger M. Lyons, MD, Charles F. LeMaistre, MD

Blood (2013) 122 (21): 2978.

https://doi.org/10.1182/blood.V122.21.2978.2978

Published: 2013

Journal Articles

Provider and Center Characteristics Of US Transplant Centers and Their Association With Survival After Allogeneic Hematopoietic Cell Transplantation (HCT) In Adults: Results From a National Survey Conducted By The Center For International Blood and Marrow Transplant Research (CIBMTR)

Navneet S. Majhail, MD, MS, Tammy Payton, BS, Lih-Wen Mau, PhD, MPH, Jennifer Le Rademacher, PhD, Pintip Chitphakdithai, PhD, Michael Eckrich, MD, Steven Joffe, MD, MPH, Stephanie J. Lee, MD, MPH, Charles F. LeMaistre, MD, Fausto R. Loberiza, Jr., MD, MS, Brent R. Logan, PhD, Elizabeth A Murphy, RN, ScD, Susan K. Parsons, MD, MRP, Ramona Repaczki-Jones, J. Douglas Rizzo, MD, Pam Robinett, Ellen Denzen, MS

Blood (2013) 122 (21): 1687.

https://doi.org/10.1182/blood.V122.21.1687.1687

Published: 2013

Journal Articles

Survival Improvements Following Myeloablative Allogeneic Hematopoietic Cell Transplantation For Acute Lymphoblastic Leukemia In Adolescents and Young Adults Have Been Comparable To Younger Children: A Study From The Cibmtr

William A. Wood, MD, MPH, Stephanie J. Lee, MD, MPH, Ruta Brazauskas, PhD, Zhiwei Wang, MS, Mahmoud D. Aljurf, MD, Karen K. Ballen, MD, David K. Buchbinder, MD, MSHS, Jason Dehn, MPH, CHTC, César O Freytes, MD, Hillard M. Lazarus, MD, Charles F. LeMaistre, MD, Paulette Mehta, MD, MPH, David Szwajcer, MD, FRCPC, Steven Joffe, MD, MPH, Navneet S. Majhail, MD, MS

Blood (2013) 122 (21): 554.

https://doi.org/10.1182/blood.V122.21.554.554

Published: 2013

Journal Articles

High Correlation of Pre-Apheresis Peripheral Blood CD34+ Cell Counts with Final Apheresis Product CD34+ Cell Count by Using a More Accurate Determination of Patient Blood Volume

Brandon Parker, James Hastings, Jill Folkert, RN, Gayla Nagy, RN, Carlos Bachier, MD, Charles F. LeMaistre, MD, Paul Shaughnessy, MD

Blood (2011) 118 (21): 2996.

https://doi.org/10.1182/blood.V118.21.2996.2996

Published: 2011

Journal Articles

Mismatches in Ethnicity Between Donor and Recipient Affects Overall Survival In Umbilical Cord Blood Transplantation,

Patali Shikhi Cheruku, Veronica H. Jude, MD, Renee M Madden, MD, Charles F. LeMaistre, MD, Ka Wah Chan, MD, MBBS, Paul Shaughnessy, MD, Carlos Bachier, MD

Blood (2011) 118 (21): 4159.

https://doi.org/10.1182/blood.V118.21.4159.4159

Published: 2011

Journal Articles

Seizures During Infusion of Autologous Peripheral Blood Stem Cells Are Related to High White Blood Cell Concentration in the Peripheral Blood Stem Cell Product and Can Be Prevented by Dilution of Product with Autologous Plasma

Carlos Bachier, MD, Grant Potter, Joshua Potter, Charles F. LeMaistre, MD, Paul Shaughnessy, MD, Kawah Chan, MD, Veronica H. Jude, MD, Renee Madden

Blood (2011) 118 (21): 4386.

https://doi.org/10.1182/blood.V118.21.4386.4386

Published: 2011

Journal Articles

Upfront Tandem Autologous Stem Cell Transplant Is Superior to Autologous or Allogeneic Stem Cell Transplant After Failure of a 1st Autologous Transplant,

Adrian Wong, MD, Charles F. LeMaistre, MD, Paul Shaughnessy, MD, Carlos Bachier, MD

Blood (2011) 118 (21): 4094.

https://doi.org/10.1182/blood.V118.21.4094.4094

Published: 2011

Journal Articles

Oral Loading of Tacrolimus and Sub-Therapeutic Levels on the Day of Transplant Do Not Predict the Incidence of Acute Graft Versus Disease or Survival After Allogeneic Stem Cell Transplant

Jill MacPherson, FNP-BC, AOCNP, Carlos Bachier, MD, Charles F. LeMaistre, MD, Hannah Sowell, RN, Luis Garcia, RN, Alessandra Curel-Sanchez, RN, Wilma Cain, RN, Ursula Caga, RN, Jeremy Means, RN, Paul Shaughnessy, MD

Blood (2011) 118 (21): 4543.

https://doi.org/10.1182/blood.V118.21.4543.4543

Published: 2011

Journal Articles

Relationship of Race/Ethnicity and Survival After Single Umbilical Cord Blood Transplantation

Karen K. Ballen, MD, John P. Klein, Ph.D., Tanya L. Pedersen, MPH, Joanne Kurtzberg, MD, Hillard M. Lazarus, MD, FACP, Charles F. LeMaistre, MD, Paulette Mehta, M.D, MPH, Jeanne Palmer, MD, Michelle Setterholm, John R. Wingard, MD, Steven Joffe, MD, MPH, Susan K. Parsons, MD, MRP, Galen E. Switzer, PhD, Stephanie J. Lee, MD, MPH, J. Douglas Rizzo, MD, MS, Navneet S. Majhail, MD, MS, for the Health Policy Working Committee of the CIBMTR

Blood (2010) 116 (21): 224.

https://doi.org/10.1182/blood.V116.21.224.224

Published: 2010

Journal Articles

Collection of Autologous Peripheral Blood Stem Cells Using the COBE Spectra Is Associated with Higher CD34+ Yields and Requires Less Collection Time Than the Fresenius AS104 Cell Separator.

Grant W Potter, Charles F. LeMaistre, MD, Paul Shaughnessy, MD, Miguel Islas, MD, Juan Huerta, Carlos Bachier, MD

Blood (2009) 114 (22): 2158.

https://doi.org/10.1182/blood.V114.22.2158.2158

Published: 2009

Journal Articles

Clinical and Cost Outcomes of Double Umbilical Cord Blood Versus Bone Marrow and Peripheral Blood Unrelated Hematopoietic Stem Cell Transplants.

Guillermo López-González, Charles F. LeMaistre, MD, Carlos Bachier, MD, Brad Smith, PhD, Ka Wah Chan, MBBS, Michael Grimley, MD, Wilma Cain, Elina Delgado, Shawn Kaleel, Paul Shaughnessy, MD

Blood (2008) 112 (11): 967.

https://doi.org/10.1182/blood.V112.11.967.967

Published: 2008

Journal Articles

Cost Analysis of Mobilization and Autologous Transplantation in Patients Who Received AMD 3100 after Failing Standard Mobilization.

Elina Delgado, Charles F. LeMaistre, MD, Carlos Bachier, Brad Smith, PhD, Guillermo López-González, Maureen Hougham, Shawn Kaleel, Paul Shaughnessy, MD

Blood (2008) 112 (11): 2151.

https://doi.org/10.1182/blood.V112.11.2151.2151

Published: 2008

Journal Articles

Interleukin-2 and Granulocyte-Macrophage Colony Stimulating Factor Is an Alternative to Donor Lymphocyte Infusion for Relapse after Allogeneic Stem Cell Transplantation and Is Associated with Increase Immune Effector Cells and Polarization to Type 2 Dendritic Cells.

Carlos R. Bachier, MD, Paul Shaughnessy, MD, Brad Smith2, PhD, Richard Salinas, Charles F. LeMaistre, MD

Blood (2007) 110 (11): 1647.

https://doi.org/10.1182/blood.V110.11.1647.1647

Published: 2007

Journal Articles

Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States

Fausto R. Loberiza, Jr, Mei-Jie Zhang, Stephanie J. Lee, John P. Klein, Charles F. LeMaistre, Derek S. Serna, Mary Eapen, Christopher N. Bredeson, Mary M. Horowitz, J. Douglas Rizzo

Blood (2005) 105 (7): 2979–2987.

https://doi.org/10.1182/blood-2004-10-3863

Published: 2005

Journal Articles

The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase

Stephanie J. Lee, John P. Klein, Claudio Anasetti, Joseph H. Antin, Fausto R. Loberiza, Brian J. Bolwell, Charles F. LeMaistre, Mark R. Litzow, David Marks, Edmund K. Waller, Marie Matlack, Sergio Giralt, Mary M. Horowitz

Blood (2001) 98 (12): 3205–3211.

https://doi.org/10.1182/blood.V98.12.3205

Published: 2001

NARROW

Bendamustine Versus Fludarabine and Cyclophosphamide for Lymphodepletion Prior to CAR-T Therapy

Standardization of Outpatient Care after CAR-T Therapy across a Large Cell Therapy Network- through Technology and Decentralized Virtual Nurses: Preliminary Results

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled Study

Do Hematopoietic Cell Transplant Patients Treated on a Clinical Trial Do Better? Comparison of Characteristics and Outcomes of Patients Enrolled Versus Not Enrolled on Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial

The VIP (Very Immunocompromised Patient) Protocol: Improved Access To Care and Time To Antibiotics

Provider and Center Characteristics Of US Transplant Centers and Their Association With Survival After Allogeneic Hematopoietic Cell Transplantation (HCT) In Adults: Results From a National Survey Conducted By The Center For International Blood and Marrow Transplant Research (CIBMTR)

Survival Improvements Following Myeloablative Allogeneic Hematopoietic Cell Transplantation For Acute Lymphoblastic Leukemia In Adolescents and Young Adults Have Been Comparable To Younger Children: A Study From The Cibmtr

High Correlation of Pre-Apheresis Peripheral Blood CD34+ Cell Counts with Final Apheresis Product CD34+ Cell Count by Using a More Accurate Determination of Patient Blood Volume

Mismatches in Ethnicity Between Donor and Recipient Affects Overall Survival In Umbilical Cord Blood Transplantation,

Seizures During Infusion of Autologous Peripheral Blood Stem Cells Are Related to High White Blood Cell Concentration in the Peripheral Blood Stem Cell Product and Can Be Prevented by Dilution of Product with Autologous Plasma

Upfront Tandem Autologous Stem Cell Transplant Is Superior to Autologous or Allogeneic Stem Cell Transplant After Failure of a 1st Autologous Transplant,

Oral Loading of Tacrolimus and Sub-Therapeutic Levels on the Day of Transplant Do Not Predict the Incidence of Acute Graft Versus Disease or Survival After Allogeneic Stem Cell Transplant

Relationship of Race/Ethnicity and Survival After Single Umbilical Cord Blood Transplantation

Collection of Autologous Peripheral Blood Stem Cells Using the COBE Spectra Is Associated with Higher CD34+ Yields and Requires Less Collection Time Than the Fresenius AS104 Cell Separator.

Clinical and Cost Outcomes of Double Umbilical Cord Blood Versus Bone Marrow and Peripheral Blood Unrelated Hematopoietic Stem Cell Transplants.

Cost Analysis of Mobilization and Autologous Transplantation in Patients Who Received AMD 3100 after Failing Standard Mobilization.

Interleukin-2 and Granulocyte-Macrophage Colony Stimulating Factor Is an Alternative to Donor Lymphocyte Infusion for Relapse after Allogeneic Stem Cell Transplantation and Is Associated with Increase Immune Effector Cells and Polarization to Type 2 Dendritic Cells.

Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States

The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only